RYZ101 for HR+/HER2- Breast Cancer
Over 2 million new cases of breast cancer are diagnosed each year, and an estimated 13.1 percent of women in the United States will be diagnosed with breast cancer in their lifetime.1, 2 Estrogen receptor positive (or ER positive) HER2 negative diagnoses account for 70% of all new breast cancer patients. Approximately 25,000 ER positive HER2 negative patients express SSTR.3
We are evaluating RYZ101 in a Phase 1/2 study in patients with histologically proven, ER positive, HER2 negative, unresectable or metastatic breast cancer expressing somatostatin receptors (SSTR), that has progressed after at least 2 lines of prior chemotherapy or antibody-drug conjugates.
Patients with hormone-refractory, HR+ advanced breast cancer have very few options after multiple lines of treatment. There are also few agents in development for this population. RYZ101 may provide a promising new option of treatment for this population with high unmet medical need.
Details of the study can be found on https://clinicaltrials.gov/study/NCT06590857
